Literature DB >> 29789189

Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016.

Helio S Sader1, Mariana Castanheira2, Leonard R Duncan2, Robert K Flamm2.   

Abstract

A total of 18,656 Enterobacteriaceae and 4,175 Pseudomonas aeruginosa were consecutively collected from 85 US hospitals and tested for susceptibility by broth microdilution methods in a central monitoring laboratory (JMI Laboratories). The antimicrobial susceptibility and frequency of key resistance phenotypes were assessed and stratified by infection type as follows: bloodstream (BSI; 3,434 isolates; 15.0%), pneumonia (6,439; 28.2%), skin and skin structure (SSSI; 4,134; 18.1%), intra-abdominal (IAI; 951; 4.2%), and urinary tract (UTI; 7,873; 34.5%). Ceftazidime-avibactam was active against 99.9% to 100.0% of Enterobacteriaceae and 97.0% (pneumonia) to 99.4% (UTI) of P. aeruginosa isolates. Susceptibility rates were consistently lower for β-lactams, such as ceftazidime (82.3% vs. 87.1-90.8%), piperacillin-tazobactam (87.5% vs. 90.2-95.6%), and meropenem (96.8% vs. 98.4-99.4%) among Enterobacteriaceae from pneumonia compared to other infection types. Susceptibility to gentamicin was also generally lower among isolates from pneumonia, whereas susceptibility to levofloxacin and colistin were lowest among BSI and SSSI isolates, respectively. The occurrence of multidrug-resistance (MDR; 8.2% overall), extensively drug-resistance (XDR; 1.1% overall), and carbapenem-resistant Enterobacteriaceae (CRE; 1.3% overall) phenotypes were markedly higher among isolates from patients with pneumonia compared to other infection types. Among P. aeruginosa, susceptibility rates for ceftazidime, piperacillin-tazobactam, and gentamicin were lowest among isolates from pneumonia, whereas susceptibility to meropenem was similar among isolates from BSI, pneumonia, and IAI (77.3-77.9%), and susceptibility to levofloxacin was markedly lower among UTI isolates (67.1%). The frequencies of P. aeruginosa isolates with MDR and XDR phenotypes were highest among isolates from patients with pneumonia.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ceftazidime-avibactam; Multidrug-resistant; carbapenem-resistant Enterobacteriaceae

Mesh:

Substances:

Year:  2018        PMID: 29789189     DOI: 10.1016/j.diagmicrobio.2018.04.012

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  21 in total

Review 1.  Epidemiology of β-Lactamase-Producing Pathogens.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

2.  Imipenem/Cilastatin/Relebactam Alone and in Combination against Pseudomonas aeruginosa in the In Vitro Pharmacodynamic Model.

Authors:  Iris H Chen; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

Review 3.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

4.  Hydroquinine Possesses Antibacterial Activity, and at Half the MIC, Induces the Overexpression of RND-Type Efflux Pumps Using Multiplex Digital PCR in Pseudomonas aeruginosa.

Authors:  Nontaporn Rattanachak; Sattaporn Weawsiangsang; Touchkanin Jongjitvimol; Robert A Baldock; Jirapas Jongjitwimol
Journal:  Trop Med Infect Dis       Date:  2022-07-30

5.  Impact of Extended- Versus Intermittent-Infusion Cefepime on Clinical Outcomes in Hospitalized Patients.

Authors:  Reese A Cosimi; Zachary W Howe; Lindsay M Saum
Journal:  Hosp Pharm       Date:  2020-02-28

6.  Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.

Authors:  Fatemeh Nemati Shahri; Ahdieh Izanloo; Mohammad Ali Sheikh Beig Goharrizi; Ailar Jamali; Hanieh Bagheri; Afsaneh Hjimohammadi; Abdollah Ardebili
Journal:  Int Microbiol       Date:  2022-06-14       Impact factor: 3.097

Review 7.  Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections.

Authors:  Beatriz Suay-García; María Teresa Pérez-Gracia
Journal:  Antibiotics (Basel)       Date:  2019-08-19

8.  Molecular Epidemiology of Carbapenemase-Producing Pseudomonas aeruginosa Isolated from an Iranian University Hospital: Evidence for Spread of High-Risk Clones.

Authors:  Solmaz Ohadian Moghadam; Davoud Afshar; Mohammad Reza Nowroozi; Amir Behnamfar; Amirreza Farzin
Journal:  Infect Drug Resist       Date:  2020-06-03       Impact factor: 4.003

Review 9.  Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections.

Authors:  Dana Holger; Razieh Kebriaei; Taylor Morrisette; Katherine Lev; Jose Alexander; Michael Rybak
Journal:  Antibiotics (Basel)       Date:  2021-05-11

10.  Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019.

Authors:  Sibylle H Lob; Daryl D DePestel; C Andrew DeRyke; Krystyna M Kazmierczak; Katherine Young; Mary R Motyl; Daniel F Sahm
Journal:  Open Forum Infect Dis       Date:  2021-06-16       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.